Valuation: Nutriband Inc.

Market Cap 76.58M 68.59M 63.09M 57.16M 107M 7.27B 109M 752M 302M 3.82B 287M 281M 12.06B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 72.25M 64.71M 59.52M 53.93M 101M 6.86B 103M 710M 285M 3.61B 271M 265M 11.38B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
40.85%
Yield 2025 *
-
Yield 2026 -
1 day-5.12%
1 week+9.38%
1 month-16.22%
3 months+121.05%
6 months+63.00%
Current year+38.77%
1 week 5.69
Extreme 5.69
6.66
1 month 5.65
Extreme 5.65
7.86
Current year 2.8
Extreme 2.8
9.19
1 year 2.8
Extreme 2.8
9.19
3 years 1.93
Extreme 1.927
11.78
5 years 1.53
Extreme 1.53
11.78
10 years 0.86
Extreme 0.857142
43.54
Manager TitleAgeSince
Chief Executive Officer 35 31/12/2015
Chief Executive Officer 52 -
Director of Finance/CFO 77 01/09/2020
Director TitleAgeSince
Chairman 52 20/01/2022
Director/Board Member 48 30/06/2018
Director/Board Member 35 31/12/2015
Date Insider Type Main position Quantity % Market Cap. Importance
31/01/25 Other

Founder

126,833 1.1420%
31/01/25 Option

Chief Financial Officer

212,837 1.9164%
20/03/24 Free

Chief Financial Officer

162,500 2.0745%
Change 5-day change 1-year change 3-year change Capi.($)
-5.12%+9.38%-6.39%+180.00% 76.58M
+1.56%+2.41%-14.09%+12.32% 184B
-6.38%-4.98%-18.07%+8.01% 112B
-0.59%+1.18%+6.44%+36.82% 118B
+3.42%+1.71%-41.92%+8.01% 94.58B
+0.09%-0.05%-2.06%+78.69% 63.13B
-0.46%+0.42%+4.48%+82.84% 55.66B
-0.23%-0.52%+10.73%-21.72% 53.9B
-4.30%-1.64%-12.44%+37.99% 43.42B
+0.58%+2.00%-1.17%-8.82% 34.68B
Average -1.14%+0.99%-7.45%+41.41% 75.93B
Weighted average by Cap. -0.49%+0.23%-10.14%+23.75%

Financials

2025 2026
Net sales 2.14M 1.92M 1.76M 1.6M 2.99M 203M 3.04M 21.02M 8.44M 107M 8.03M 7.86M 337M 2.04M 1.82M 1.68M 1.52M 2.84M 193M 2.89M 20.01M 8.03M 102M 7.64M 7.48M 321M
Net income -10.48M -9.39M -8.64M -7.82M -14.63M -995M -14.9M -103M -41.34M -524M -39.34M -38.5M -1.65B -8.23M -7.37M -6.78M -6.14M -11.48M -781M -11.7M -80.85M -32.46M -411M -30.88M -30.23M -1.3B
Net Debt -4.13M -3.69M -3.4M -3.08M -5.76M -392M -5.86M -40.53M -16.27M -206M -15.48M -15.15M -650M -4.33M -3.88M -3.57M -3.23M -6.04M -411M -6.15M -42.53M -17.07M -216M -16.25M -15.9M -682M
Projected Income Statement - Annual - Nutriband Inc.
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
30/10/26 US$6.300 -5.12% 22,233
29/10/26 US$6.640 +3.75% 12,615
28/10/26 US$6.400 +7.56% 71,081
27/10/26 US$5.950 -0.34% 11,707
26/10/26 US$5.970 +3.65% 26,644
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.300USD
Average target price
15.00USD
Spread / Average Target
+138.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nutriband Inc.
  1. Stock Market
  2. Stocks
  3. NTRB Stock